No influence of the polymorphisms <it>CYP2C19 </it>and <it>CYP2D6 </it>on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
<p>Abstract</p> <p>Background</p> <p>The response to treatment varies among patients with multiple myeloma and markers for prediction of treatment outcome are highly needed. Bioactivation of cyclophosphamide and thalidomide, and biodegradation of bortezomib, is dependen...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-08-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/10/404 |